Education
About Us
Working with TipRanks
Follow Us
Almirall SA (GB:0O9B)
LSE:0O9B
0O9B Stock Chart & Stats
€12.90
-€0.04(-0.52%)
At close: 4:00 PM EST
€12.90
-€0.04(-0.52%)
Day’s Range― - ―
52-Week Range€8.74 - €13.98
Previous CloseN/A
Volume457.00
Average Volume (3M)2.60K
Market Cap
€2.76B
Enterprise Value€2.80B
Total Cash (Recent Filing)€338.82M
Total Debt (Recent Filing)€359.66M
Price to Earnings (P/E)59.4
Beta1.07
Next Earnings
May 11, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.09
Shares Outstanding214,785,200
10 Day Avg. Volume4,186
30 Day Avg. Volume2,602
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.85
Price to Sales (P/S)2.47
P/FCF Ratio20.54
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€13.65Price Target Upside5.81% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.44
Revenue Forecast (FY)€1.23B
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryA clear top-line recovery to ~€1.11B in 2025 reflects restored commercial traction in Almirall's core dermatology portfolio. Sustained revenue growth from 2021–2025 indicates improving market position and product demand, supporting mid‑term cash generation and investment capacity.
Improved Cash GenerationOperating cash flow turning consistently positive and a sizeable FCF rebound in 2025 materially strengthen the firm's ability to fund R&D, support launches, and meet obligations without relying on external financing. This improves financial flexibility over the coming quarters.
Manageable, Improving LeverageModerate and improving leverage (D/E ~0.24) and a solid capital base enhance resilience to R&D cadence and cyclical pressures. A stronger balance sheet supports strategic options—partnerships, selective M&A, or sustained investment in dermatology—over the medium term.
Bears Say
Earnings And FCF VolatilityHistoric swings in profitability and cash generation reduce predictability of free cash flow and make multi‑period planning harder. This volatility increases execution risk for launches and R&D projects and can constrain consistent capital returns or reinvestment over the next several quarters.
Low Returns On EquityA persistently low ROE signals limited efficiency in converting equity into profitable growth. Even with recent recovery, such muted returns imply the company must materially lift margins or grow revenues faster to generate sustainable shareholder value over the medium term.
Thin And Uneven MarginsModest operating and net margins provide little cushion against pricing pressure, higher R&D or commercial spend, or competitive incursions. The prior years' losses and thin margins raise concern that profitability is not yet robust enough to be durable without continued execution and portfolio strength.
Almirall News
0O9B FAQ
What was Almirall SA’s price range in the past 12 months?
Almirall SA lowest share price was €8.74 and its highest was €13.98 in the past 12 months.
What is Almirall SA’s market cap?
Almirall SA’s market cap is €2.76B.
When is Almirall SA’s upcoming earnings report date?
Almirall SA’s upcoming earnings report date is May 11, 2026 which is in 74 days.
How were Almirall SA’s earnings last quarter?
Almirall SA released its earnings results on Feb 23, 2026. The company reported €0.091 earnings per share for the quarter, missing the consensus estimate of €0.16 by -€0.069.
Is Almirall SA overvalued?
According to Wall Street analysts Almirall SA’s price is currently Undervalued.
Does Almirall SA pay dividends?
Almirall SA does not currently pay dividends.
What is Almirall SA’s EPS estimate?
Almirall SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Almirall SA have?
Almirall SA has 214,785,200 shares outstanding.
What happened to Almirall SA’s price movement after its last earnings report?
Almirall SA reported an EPS of €0.091 in its last earnings report, missing expectations of €0.16. Following the earnings report the stock price went down -5.821%.
Which hedge fund is a major shareholder of Almirall SA?
Currently, no hedge funds are holding shares in GB:0O9B
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Almirall Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€13.65 (5.81% Upside)
€13.65 (5.81% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
36.06%
12-Months-Change
Fundamentals
Return on Equity
1.45%
Trailing 12-Months
Asset Growth
-0.58%
Trailing 12-Months
Company Description
Almirall SA
Almirall, S.A., a biopharmaceutical company, engages in the research, development, manufacture, and sale of skin-health related medicines in Europe, the United States, and internationally. The company offers its products for dermatological diseases comprising actinic keratosis, atopic dermatitis, androgenic alopecia, psoriasis, onychomycosis, oncodermatology, acne, and orphan indications, as well as for cardiovascular, musculo-skeletal, respiratory, and nervous system; alimentary tract and metabolism; antiinfectives for systemic use; genito urinary system and sex hormones; immunostimulants; and systematic hormonal preparations. Its products include Ilumetri, Solaraze, Actikerall, Ciclopoli, Skilarence, Aczone, Decoderm, Cordran Tape, Azelex, Klisyri, Tazorac, Seysara, Veltin, Almax, Ebastel, Sativex, Crestor, and Efficib/Tesavel. Almirall, S.A. has collaboration and partnership agreements with Tyris Therapeutics, BIOMAP, the University of Dundee, Kaken Pharmaceutical Co Ltd., Ichnos Sciences Inc., the University Carlos III Madrid and MEDINA Foundation, 23andMe, Inc., HitGen Ltd., WuXi Biologics, Eli Lilly and Company, and Athenex, Inc. The company was formerly known as Laboratorios Almirall, S.A. and changed its name to Almirall, S.A. in May 2009. Almirall, S.A. was founded in 1943 and is headquartered in Barcelona, Spain.
0O9B Stock 12 Month Forecast
Average Price Target
€13.65
▲(5.81% Upside)
Technical Analysis
Faes Farma
―
Grifols
―
LABORATORIO REIG JOFRE
―
Laboratorios Farmaceuticos Rovi
―
Pharma Mar SA
―
Options Prices
Currently, No data available
---